Fecal S100A12 in Takayasu arteritis predicts disease activity and intestinal involvement

Cem, Simsek; Armağan, Berkan; Sari, Alper; Emet, Abdülsamet; Kılıç, Levent; Akdoğan, A.

doi:10.1007/s00296-021-04981-6

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study of 29 patients with TAK (11 with active disease) reported higher levels of fecal S100A12 in active TAK. Fecal S100A12 levels demonstrated a significant moderate correlation with ITAS2010 but not with ESR or CRP [ 137 ].…”

Section: Circulating Biomarkers Of Disease Activity In Takmentioning

confidence: 99%

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

et al. 2022

View full text Add to dashboard Cite

Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the National Institutes of Health (NIH) score, the Disease Extent Index in TAK (DEI.TAK) and the Indian TAK Clinical Activity Score (ITAS2010) inconsistently associate with acute phase reactants (APRs). Computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or color Doppler Ultrasound (CDUS) enables anatomical characterization of stenosis, dilatation, and vessel wall characteristics. Vascular wall uptake of 18-fluorodeoxyglucose or other ligands using positron emission tomography computerized tomography (PET-CT) helps assess metabolic activity, which reflects disease activity well in a subset of TAK with normal APRs. Angiographic scoring systems to quantitate the extent of vascular involvement in TAK have been developed recently. Erythrocyte sedimentation rate and C-reactive protein have a moderate performance in distinguishing active TAK. Numerous novel biomarkers are under evaluation in TAK. Limited literature suggests a better assessment of active disease by combining APRs, PET-CT, and circulating biomarkers. Validated damage indices and patient-reported outcome measures specific to TAK are lacking. Few biomarkers have been evaluated to reflect vascular damage in TAK and constitute important research agenda.

show abstract

Section: Circulating Biomarkers Of Disease Activity In Takmentioning

confidence: 99%

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

et al. 2022

View full text Add to dashboard Cite

show abstract

Systematic analysis and characterization of long non-coding RNA genes in inflammatory bowel disease

Velissari,

Ilieva,

Dao

et al. 2023

Briefings in Functional Genomics

View full text Add to dashboard Cite

The cases of inflammatory bowel disease (IBD) are increasing rapidly around the world. Due to the multifactorial causes of IBD, there is an urgent need to understand the pathogenesis of IBD. As such, the usage of high-throughput techniques to profile genetic mutations, microbiome environments, transcriptome and proteome (e.g. lipidome) is increasing to understand the molecular changes associated with IBD, including two major etiologies of IBD: Crohn disease (CD) and ulcerative colitis (UC). In the case of transcriptome data, RNA sequencing (RNA-seq) technique is used frequently. However, only protein-coding genes are analyzed, leaving behind all other RNAs, including non-coding RNAs (ncRNAs) to be unexplored. Among these ncRNAs, long non-coding RNAs (lncRNAs) may hold keys to understand the pathogenesis of IBD as lncRNAs are expressed in a cell/tissue-specific manner and dysregulated in a disease, such as IBD. However, it is rare that RNA-seq data are analyzed for lncRNAs. To fill this gap in knowledge, we re-analyzed RNA-seq data of CD and UC patients compared with the healthy donors to dissect the expression profiles of lncRNA genes. As inflammation plays key roles in the pathogenesis of IBD, we conducted loss-of-function experiments to provide functional data of IBD-specific lncRNA, lung cancer associated transcript 1 (LUCAT1), in an in vitro model of macrophage polarization. To further facilitate the lncRNA research in IBD, we built a web database, IBDB (https://ibd-db.shinyapps.io/IBDB/), to provide a one-stop-shop for expression profiling of protein-coding and lncRNA genes in IBD patients compared with healthy donors.

show abstract

Medium-vessel and large-vessel vasculitis in children

Scott

Stander

Phoya

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This article serves as an up-to-date examination of the latest findings in the field of paediatric large-vessel and medium-vessel vasculitis. Recent findings Over the last 2 years and in the wake of SARS-CoV2 pandemic, a multitude of studies have increased our insight into these conditions. Although large-vessel and medium-vessel vasculitis are uncommon amongst children, they are a complex and multisystem with a constantly evolving landscape. Increasing numbers of reports from low-income and middle-income countries are shaping our understanding of the epidemiology of vasculitis in children. The influence of infectious disease and the microbiome are of particular interest in unravelling pathogenetic aspects. Improved understanding of the genetics and immunology offer opportunities for better diagnostic options and biomarkers of disease as well as targeted therapies. Summary In this review, we address recent findings in epidemiology, pathophysiology, clinical findings, bio-markers, imaging and treatment that have the potential to offer better management solutions for these uncommon conditions.

show abstract

Fecal S100A12 in Takayasu arteritis predicts disease activity and intestinal involvement

Cited by 3 publications

References 31 publications

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

Systematic analysis and characterization of long non-coding RNA genes in inflammatory bowel disease

Medium-vessel and large-vessel vasculitis in children

Contact Info

Product

Resources

About